SCHEMBL2693586

SCHEMBL2693586

CC(C)CN1CCCC2(CCN(Cc3ccc(C(=O)N(Cc4ncc[nH]4)Cc4ncc[nH]4)cc3)CC2)C1

nearest known ligand 0.93

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.93
CYP3A4 P08684 15/20 0.48
CYP2D6 P10635 11/20 0.48
CYP1A2 P05177 4/20 0.48
OPRD1 P41143 1/20 0.45
USP2 O75604 6/20 0.44
ALDH1A1 P00352 4/20 0.44
CYP2C9 P11712 4/20 0.42
TSHR P16473 4/20 0.42
CYP2C19 P33261 1/20 0.41
ALOX15 P16050 1/20 0.41
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
RCOR1 Q9UKL0 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695352 0.97 CXCR4 (0.87) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2694483 0.97 CXCR4 (1.00) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL1793937 0.93 CXCR4 (0.93) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2695823 0.93 CXCR4 (0.93) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2695642 0.91 CXCR4 (0.90) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2697475 0.91 CXCR4 (0.90) CXCR4CYP3A4CYP2D6OPRD1ALDH1A1
SCHEMBL1793784 0.89 CXCR4 (0.74) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2694095 0.89 CXCR4 (0.85) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL1798887 0.89 CXCR4 (0.73) CXCR4CYP3A4CYP2D6CYP1A2OPRD1
SCHEMBL2696120 0.88 CXCR4 (0.73) CXCR4CYP3A4CYP2D6CYP1A2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885CYP3A4 3747/4885CYP2D6 2687/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885CYP3A4 4052/4885CYP2D6 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.